Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 1/20 | 0.38 |
| ▸ | CCR1 | P32246 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
| ▸ | CCR8 | P51685 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.31 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.30 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.30 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25820108 | 0.77 | IP6K1 (0.43) | ADKELANE | |
| SCHEMBL25820134 | 0.74 | HTR1A (0.53) | CCR1CCR5CCR8HTR1AADRA1D | |
| SCHEMBL25825506 | 0.73 | CCNC (0.39) | CCR1CCR5CCR8HTR1AADRA1D | |
| SCHEMBL25820133 | 0.66 | HTR1A (0.53) | CCR1CCR5CCR8HTR1AADRA1D | |
| SCHEMBL23976247 | 0.65 | SIRT2 (0.43) | ADKADRA1DADRA1AADRA1B | |
| SCHEMBL25820095 | 0.65 | HTR1A (0.51) | CCR1CCR5CCR8HTR1AADRA1D | |
| SCHEMBL25820101 | 0.64 | PDE3B (0.44) | ADKELANE | |
| SCHEMBL2494065 | 0.63 | LOXL2 (0.58) | HTR1AADRA1DADRA1AADRA1BELANE | |
| SCHEMBL26664503 | 0.63 | GABRA1 (0.47) | HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL18924519 | 0.63 | CYP1A2 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183226-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | ADK 1235/4885CCR1 4312/4885CCR5 4140/4885 |
| US-20230219927-A1 | AKT3 MODULATORS | AKT3, AKT2, PIK3CA | ADK 1021/4885CCR1 3960/4885CCR5 4091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.